Skip to main content
Equibles

WELLS FARGO & COMPANY/MN

Position in AKTS — Aktis Oncology, Inc.

CIK 72971 SAN FRANCISCO, CA
Back to AKTS Full portfolio

Position in AKTS

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$891,448
+$755,288 QoQ
Shares Held
27,659
+263.4% QoQ
Ownership
0.050%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#51
of 114 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in AKTS Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

WELLS FARGO & COMPANY/MN holds $1,575,562,942 across 417 Biotechnology names. AKTS ranks #144 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 749,528 $372,313,040
2 HALO
Halozyme Therapeutics, Inc.
 1,390,428 $108,828,797
3 ALNY
Alnylam Pharmaceuticals, Inc.
 310,047 $93,333,446
4 REGN
Regeneron Pharmaceuticals, Inc.
 140,802 $87,795,677
5 EXEL
Exelixis, Inc.
 717,840 $39,057,673
6 RVMD
Revolution Medicines, Inc.
 178,780 $33,481,916
7 ARGX
Argenx SE
 34,453 $31,964,458
8 INCY
Incyte Corp
 255,064 $28,914,053

All Filings in AKTS

Export CSV
2 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $891,448 27,659
2026-03-31 $136,160 7,611